Trial of LBH589 in Metastatic Thyroid Cancer

Summary

The purpose of this study is to evaluate the tumor response rate in patients with metastatic medullary thyroid cancer (MTC) or radioiodine resistant differentiated thyroid cancer (DTC) after receiving treatment with LBH589 20 mg by mouth, three times weekly. Time to progression, overall survival, toxicity, tolerability, and Notch1 protein expression patterns will also be evaluated.

Timeline

Start

2010-01

Primary completion

2013-08

Completion

2016-02

Drugs

Indications